Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90bn off the valuation of Europe’s largest company by market capitalisation.
CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of Mounjaro, a rival treatment from Eli Lilly.
您已阅读13%（526字），剩余87%（3662字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。